Thema: Presse: Experts guide brain cancer vaccine development
Presse: Experts guide brain cancer vaccine development
Mario[a]
02.11.2005 15:17:17
Experts guide brain cancer vaccine development
Mon 26 Sep 2005
Northwest Biotherapeutics announced today that a Clinical Advisory Board (CAB) has been appointed to guide the Company in its late stage clinical trial for a personalized vaccine treatment for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. Northwest Biotherapeutics´ vaccine, DCVax(R)-Brain, uses a patient´s own dendritic cells to mobilize the body´s full immune system against cancer. DCVax(R)-Brain showed very promising results in two Phase I clinical trials and a large, multi-center Phase II clinical trial is planned for this Fall.
Comprised of world-renowned oncologists, neurosurgeons, neurologists and neuroscientists, the Clinical Advisory Board will play an important role in guiding the upcoming large Phase II trial. In addition, it is anticipated that the leading medical centers with which the CAB members are affiliated may be among the first sites at which enrollment for the Phase II trial will begin.
"We are proud to have such a distinguished Clinical Advisory Board with some of the world´s most respected and experienced experts in the fields of brain cancer, neurology, and clinical design, who will work together to advance our personalized vaccines for the benefit of patients with Glioblastoma multiforme," said Alton Boynton, Ph.D., President and Chief Operating Officer of Northwest Biotherapeutics.
Linda Liau, M.D., Ph.D., a neurosurgeon from the University of California at Los Angeles (UCLA) served as principal investigator for two Phase I clinical trials of DCVax(R)-Brain in patients with newly diagnosed and recurrent GBM, and will Chair Northwest Biotherapeutics´ Clinical Advisory Board for DCVax(R)-Brain. "DCVax(R)-Brain has shown outstanding therapeutic promise in early clinical testing. We have patients living cancer-free and exceeding standard survival times for GBM, the most aggressive form of brain cancer. The Clinical Advisory Board is eager to begin its work to advance the development of DCVax(R)-Brain so that an increasing number of patients will have access to it as soon as possible."
The Northwest Biotherapeutics Clinical Advisory Board for DCVax(R)-Brain is comprised of:
Linda Liau, M.D., Ph.D. - Chair - Dr. Liau is Director of the Malignant Brain Tumor Program at the UCLA School of Medicine, and an Associate Professor of Neurosurgery at the University of California at Los Angeles (UCLA). Dr. Liau is a well-respected neurosurgeon and has served as a clinical investigator for trials of investigational new drugs. She serves on the Editorial Boards of the Journals of Neuro-Oncology, Neuro-Oncology, and Surgical Neurology. She holds a B.S. and B.A. from Brown University, an M.D. from Stanford and a Ph.D. in Molecular Neuroscience from UCLA.
Darell D. Bigner, M.D., Ph.D. - Dr. Bigner serves as the Edwin L. Jones, Jr. and Lucille Finch Jones Cancer Research Professor of Pathology, and Professor of Surgery at the Duke Comprehensive Cancer Center, Duke University Medical Center. He is also Chief of the Division of Experimental Pathology Research and Vice Chair of Research in the Department of Surgery. Dr. Bigner´s main area of research is the causes, mechanisms of transformation and altered growth control and new therapy for primary and metastatic tumors of the central nervous system. Dr. Bigner holds a B.S. from the University of Georgia, and an M.D. and Ph.D. from Duke University.
Henry Brem, M.D. - Dr. Henry Brem is the Director of the Department of Neurosurgery, Harvey Cushing Professor of Neurosurgery, Professor of Ophthalmology, and Oncology for The Johns Hopkins Hospital. He is also Director of the Hunterian Neurosurgical Research Laboratory at Johns Hopkins. His practice specializes in the surgical treatment of pituitary tumors, meningiomas, skull base tumors, and other solid brain tumors. He has developed new clinical treatments for brain tumors including the local delivery of chemotherapeutic agents in biodegradable polymers, Gliadel wafer, for which a patent was issued and a product approved by the FDA. Dr. Brem received his A.B. from New York University, and M.D. from Harvard Medical School.
Tom Mikkelsen, M.D. - Dr. Mikkelsen serves in the Eugene and Marcia Applebaum Lab of Molecular Therapeutics and is Co-Director, Hermelin Brain Tumor Center, Josephine Ford Cancer Center, at the Henry Ford Hospital Detroit, Michigan. Dr. Mikkelsen is also Staff Neuro-Oncologist, Division of Neurology, Department of Medicine, for the William Beaumont Cancer Center, in Royal Oak, Michigan. Dr. Mikkelsen received his B.S. degree from the University of Alberta and his M.D. from the University of Calgary.
Steven S. Brem, M.D. - Dr. Brem is Chief of the Neurosurgery Service, Director, Neuro-Oncology research laboratory, and Division Chief, Neuro-Oncology, for the H. Lee Moffitt Cancer Center and Research Institute of the University of South Florida. Dr. Brem also serves as a New Approaches to Brain Tumor Therapy (NABTT) Investigator. His research interests include frameless image-guided surgery, surgery of brain metastasis and malignant tumors, experimental therapeutics, anti-angiogenesis therapies, pituitary surgery and skull base surgery. Dr. Brem received a B.A. from Rutgers University and an M.D. from Harvard Medical School.
Mon 26 Sep 2005
Northwest Biotherapeutics announced today that a Clinical Advisory Board (CAB) has been appointed to guide the Company in its late stage clinical trial for a personalized vaccine treatment for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. Northwest Biotherapeutics´ vaccine, DCVax(R)-Brain, uses a patient´s own dendritic cells to mobilize the body´s full immune system against cancer. DCVax(R)-Brain showed very promising results in two Phase I clinical trials and a large, multi-center Phase II clinical trial is planned for this Fall.
Comprised of world-renowned oncologists, neurosurgeons, neurologists and neuroscientists, the Clinical Advisory Board will play an important role in guiding the upcoming large Phase II trial. In addition, it is anticipated that the leading medical centers with which the CAB members are affiliated may be among the first sites at which enrollment for the Phase II trial will begin.
"We are proud to have such a distinguished Clinical Advisory Board with some of the world´s most respected and experienced experts in the fields of brain cancer, neurology, and clinical design, who will work together to advance our personalized vaccines for the benefit of patients with Glioblastoma multiforme," said Alton Boynton, Ph.D., President and Chief Operating Officer of Northwest Biotherapeutics.
Linda Liau, M.D., Ph.D., a neurosurgeon from the University of California at Los Angeles (UCLA) served as principal investigator for two Phase I clinical trials of DCVax(R)-Brain in patients with newly diagnosed and recurrent GBM, and will Chair Northwest Biotherapeutics´ Clinical Advisory Board for DCVax(R)-Brain. "DCVax(R)-Brain has shown outstanding therapeutic promise in early clinical testing. We have patients living cancer-free and exceeding standard survival times for GBM, the most aggressive form of brain cancer. The Clinical Advisory Board is eager to begin its work to advance the development of DCVax(R)-Brain so that an increasing number of patients will have access to it as soon as possible."
The Northwest Biotherapeutics Clinical Advisory Board for DCVax(R)-Brain is comprised of:
Linda Liau, M.D., Ph.D. - Chair - Dr. Liau is Director of the Malignant Brain Tumor Program at the UCLA School of Medicine, and an Associate Professor of Neurosurgery at the University of California at Los Angeles (UCLA). Dr. Liau is a well-respected neurosurgeon and has served as a clinical investigator for trials of investigational new drugs. She serves on the Editorial Boards of the Journals of Neuro-Oncology, Neuro-Oncology, and Surgical Neurology. She holds a B.S. and B.A. from Brown University, an M.D. from Stanford and a Ph.D. in Molecular Neuroscience from UCLA.
Darell D. Bigner, M.D., Ph.D. - Dr. Bigner serves as the Edwin L. Jones, Jr. and Lucille Finch Jones Cancer Research Professor of Pathology, and Professor of Surgery at the Duke Comprehensive Cancer Center, Duke University Medical Center. He is also Chief of the Division of Experimental Pathology Research and Vice Chair of Research in the Department of Surgery. Dr. Bigner´s main area of research is the causes, mechanisms of transformation and altered growth control and new therapy for primary and metastatic tumors of the central nervous system. Dr. Bigner holds a B.S. from the University of Georgia, and an M.D. and Ph.D. from Duke University.
Henry Brem, M.D. - Dr. Henry Brem is the Director of the Department of Neurosurgery, Harvey Cushing Professor of Neurosurgery, Professor of Ophthalmology, and Oncology for The Johns Hopkins Hospital. He is also Director of the Hunterian Neurosurgical Research Laboratory at Johns Hopkins. His practice specializes in the surgical treatment of pituitary tumors, meningiomas, skull base tumors, and other solid brain tumors. He has developed new clinical treatments for brain tumors including the local delivery of chemotherapeutic agents in biodegradable polymers, Gliadel wafer, for which a patent was issued and a product approved by the FDA. Dr. Brem received his A.B. from New York University, and M.D. from Harvard Medical School.
Tom Mikkelsen, M.D. - Dr. Mikkelsen serves in the Eugene and Marcia Applebaum Lab of Molecular Therapeutics and is Co-Director, Hermelin Brain Tumor Center, Josephine Ford Cancer Center, at the Henry Ford Hospital Detroit, Michigan. Dr. Mikkelsen is also Staff Neuro-Oncologist, Division of Neurology, Department of Medicine, for the William Beaumont Cancer Center, in Royal Oak, Michigan. Dr. Mikkelsen received his B.S. degree from the University of Alberta and his M.D. from the University of Calgary.
Steven S. Brem, M.D. - Dr. Brem is Chief of the Neurosurgery Service, Director, Neuro-Oncology research laboratory, and Division Chief, Neuro-Oncology, for the H. Lee Moffitt Cancer Center and Research Institute of the University of South Florida. Dr. Brem also serves as a New Approaches to Brain Tumor Therapy (NABTT) Investigator. His research interests include frameless image-guided surgery, surgery of brain metastasis and malignant tumors, experimental therapeutics, anti-angiogenesis therapies, pituitary surgery and skull base surgery. Dr. Brem received a B.A. from Rutgers University and an M.D. from Harvard Medical School.
Mario[a]
